Vor Biopharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vor Biopharma Inc. on September 17, 2025. The report details a material modification to the rights of security holders involving a reverse stock split authorized by stockholders at a Special Meeting on August 25, 2025.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only quantitative data provided relates to share counts:
- Shares Outstanding (Pre-Split): 136,822,693 shares as of September 16, 2025.
- Shares Outstanding (Post-Split): Approximately 6,841,134 shares immediately following the split.
- Split Ratio: 1-for-20.
Material Changes
The primary material change is the implementation of a 1-for-20 reverse stock split effective at 5:00 p.m. Eastern Time on September 18, 2025. Key impacts include:
- Share Conversion: Every 20 issued and outstanding shares will be converted into one share.
- Trading Resumption: Common stock will begin trading on a split-adjusted basis on the Nasdaq Global Select Market on September 19, 2025.
- New CUSIP: The new CUSIP number is 929033207.
- Equity Adjustments: Proportionate adjustments will be made to the exercise price and share counts for all outstanding stock options, warrants, and shares reserved under equity incentive plans.
- Fractional Shares: No fractional shares will be issued; holders entitled to fractional shares will receive cash payments in lieu thereof.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard implications of a reverse stock split. The document notes that the split will not affect any stockholder's percentage ownership, except where fractional shares are cashed out.
Investor Verification Checklist
- Verify the new CUSIP number (929033207) for trading purposes starting September 19, 2025.
- Confirm the adjusted exercise prices and share counts for any held stock options or warrants.
- Check brokerage accounts for cash payments in lieu of fractional shares if holding a number of shares not divisible by 20.
- Review the impact of the reduced share count on the company's ability to meet Nasdaq listing requirements.